Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry

Patrick Goldstein1 Emergency Department, Lille Regional University Hospital, Lille, FranceCorrespondence[email protected]

Niccolò Grieco2 Department of Cardiology, Hospital Niguarda Cà Granda Milano, Milan, Italy

Hüseyin Ince3 Internal Medicine Centre, Cardiology Department, Rostock University Clinic, Rostock, Germany;4 Department of Cardiology, Vivantes Klinikum im Friedrichshain and Am Urban, Berlin, Germany

Nicolas Danchin5 Department of Cardiology, European Hospital Georges-Pompidou, Paris, France

Yvonne Ramos6 Medical Department, Daiichi Sankyo Europe, Munich, Germany

Jochen Goedicke7 Medical Department, Lilly Deutschland GmbH, Bad Homburg, Germany

Peter Clemmensen8 Department of Medicine, Division of Cardiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark;9 Department of Medicine, Division of Cardiology, Nykoebing F Hospital, Copenhagen, Denmark

show all

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry

Articles from other publishers (5)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry

Citations (5)

Articles from other publishers (5)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date